ClinicalTrials.gov
public full text
Public Domain
Neoadjuvant PD-1 in Newly Diagnosed Glioblastoma
The purpose of this research is to study the safety and efficacy of Camrelizumab treating patients with newly diagnosed glioblastomas.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma#1127772
- A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma#141020
- Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG)#1007708
- Glioblastoma: epidemiology, molecular pathogenesis, diagnosis, management, and therapeutic resistance.#170593
- TH-302 in Combination With Bevacizumab for Glioblastoma#1128093
Record · ID 993872
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive